> Detailanzeige

Franchini, Massimo; Glingani, Claudia; Donno, Giuseppe De; Lucchini, Giuseppe; Beccaria, Massimiliano; Amato, Massimo; Castelli, Gian Paolo; Bianciardi, Leonardo; Pagani, Mauro; Ghirardini, Marco; Puma, Giuseppe; Presciuttini, Barbara; Costantino, Maria Teresa; Frigato, Marilena; Crosato, Verena; Tiecco, Giorgio; Mulè, Alice; Papalia, Dorothea Angela; Inglese, Francesco; Spreafico, Fabio; Garuti, Martina; Pecoriello, Antonietta; Cervi, Giulia; Greco, Graziana; [...]

Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience
  • Beteiligte: Franchini, Massimo; Glingani, Claudia; Donno, Giuseppe De; Lucchini, Giuseppe; Beccaria, Massimiliano; Amato, Massimo; Castelli, Gian Paolo; Bianciardi, Leonardo; Pagani, Mauro; Ghirardini, Marco; Puma, Giuseppe; Presciuttini, Barbara; Costantino, Maria Teresa; Frigato, Marilena; Crosato, Verena; Tiecco, Giorgio; Mulè, Alice; Papalia, Dorothea Angela; Inglese, Francesco; Spreafico, Fabio; Garuti, Martina; Pecoriello, Antonietta; Cervi, Giulia; Greco, Graziana; [...]
  • Erschienen: MDPI AG, 2022
  • Erschienen in: Life
  • Sprache: Englisch
  • DOI: 10.3390/life12030420
  • ISSN: 2075-1729
  • Schlagwörter: Paleontology ; Space and Planetary Science ; General Biochemistry, Genetics and Molecular Biology ; Ecology, Evolution, Behavior and Systematics
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80–320). Their median age was 68 years (IQR, 56–78 years), and 62% were males. At enrollment, 55% of patients had an increased body mass index (BMI), and 25.6% had at least three comorbidities. The 28-day crude mortality rate was 12.6% (51/405). Young age (&lt;68 years), mild disease (admission to low-intensity departments) and early treatment (&lt;7 days from symptoms onset) with high nAb titer (≥320) CCP were found as independently associated with a favorable response to CCP treatment. No safety concerns were recorded, with a rate of CCP-related adverse reactions (all of mild intensity) of 1.3%. In our real-life experience, the first in the western world, early administration of high-titer CCP was a safe and effective treatment for hospitalized COVID-19 patients.</jats:p>
  • Zugangsstatus: Freier Zugang